RT Journal Article
SR Electronic
T1 Impact of Indolent Schistosomiasis on Morbidity and Mortality from Respiratory Tract Infections in Preschool Age Children from a Schistosomiasis Endemic Area
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.06.20227173
DO 10.1101/2020.11.06.20227173
A1 Mduluza-Jokonya, Tariro L.
A1 Vengesai, Arthur
A1 Jokonya, Luxwell
A1 Thakataka, Amanda
A1 Midzi, Herald
A1 Mduluza, Takafira
A1 Sibanda, Elopy
A1 Naicker, Thajasvarie
YR 2020
UL http://medrxiv.org/content/early/2020/11/10/2020.11.06.20227173.abstract
AB Introduction Pneumonia is the biggest child killer, after the neonatal period. This is especially so in children from developing countries who are exposed to other infections simultaneously. In this article we investigated the impact of indolent Schistosoma haematobium infection on background of a respiratory infectionMethod A cross sectional study with 237 preschool age children with a respiratory infection, was performed during winter months in a schistosomiasis endemic area. Participants were clinically examined and investigated appropriately. Upper respiratory tract infection (URTI) and pneumonia were defined and classified as per IMCI and WHO guidelines, respectively. S. haematobium infection diagnosis was by urine filtration on urine collected over three consecutive days. Data was analysed using SPSS.Results S haematobium infection prevalence was 29% (69). Prevalence of repiratory infections were as follows: common cold 79% (188), pneumonia 15% (36) and severe pneumonia 6% (15). Eighty-one percent of participants with the common cold were S. haematobium negative, whilst 80 % of those with severe pneumonia were infected. Schistosomiasis infected children were at greater odds of developing; pneumonia (aOR=3.61 (95% CI 1.73-7.55) and severe pneumonia (aOR=21.13 (95% CI 4.65-95.89). High intensity S. haematobium infection was associated with an increased risk of severe pneumonia RR= 23.78(95% CI 6.86-82.32). Mortality from coinfection emanated from severe pneumonia and severe S. haematobium infection intensity (RR= 26.56 (95% CI 1.49 to 473.89). Number needed to harm (NNH) for S. haematobium infected children who develop respiratory tract infection was 4:1 for pneumonia and 5:1 for severe pneumonia.Conclusion The study demonstrated that coinfection with Schistosomiasis increases morbidity and mortality from respiratory tract infections by up to 20 times in children less than five years old. There is need to cover schistosomiasis screening and treatment in children under 5 years old to avert mortality and morbidity due to coinfection with respiratory infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study received funding from the TIBA. This research was commissioned by the National Institute of Health Research (NIHR), Global Health Research Programme (16/136/33) using UK aid from UK Government. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from Medical Research Council of Zimbabwe (MRCZ/B/1854). Gatekeeper approval was obtained from the Provincial and District Medical Directors and Community Leaders. Informed consent was obtained from the parent/guardian of the children. All participants with confirmed disease were offered treatment and parents/caregivers were counselled. Participants with severe pneumonia signs were immediately transferred to the nearest health facility for further managementAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe statistical data on the parasitology and clinical scores used to support the findings of this study are available from the corresponding author upon request.